Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.
Mörner A, Jansson M, Bunnik EM, Schøller J, Vaughan R, Wang Y, Montefiori DC, Otting N, Bontrop R, Bergmeier LA, Singh M, Wyatt RT, Schuitemaker H, Biberfeld G, Thorstensson R, Lehner T. Mörner A, et al. Among authors: biberfeld g. J Virol. 2011 Jul;85(13):6442-52. doi: 10.1128/JVI.00129-11. Epub 2011 Apr 13. J Virol. 2011. PMID: 21490092 Free PMC article.
Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys.
Walther-Jallow L, Nilsson C, Söderlund J, Ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Walther-Jallow L, et al. Among authors: biberfeld p, biberfeld g. J Gen Virol. 2001 Jul;82(Pt 7):1601-1612. doi: 10.1099/0022-1317-82-7-1601. J Gen Virol. 2001. PMID: 11413371
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.
Bråve A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, Biberfeld G, Earl P, Moss B, Cox JH, Wahren B. Bråve A, et al. Among authors: biberfeld g. Mol Ther. 2007 Sep;15(9):1724-33. doi: 10.1038/sj.mt.6300235. Epub 2007 Jun 19. Mol Ther. 2007. PMID: 17579577 Free article.
Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes.
Aboud S, Nilsson C, Karlén K, Marovich M, Wahren B, Sandström E, Gaines H, Biberfeld G, Godoy-Ramirez K. Aboud S, et al. Among authors: biberfeld g. Clin Vaccine Immunol. 2010 Jul;17(7):1124-31. doi: 10.1128/CVI.00008-10. Epub 2010 May 12. Clin Vaccine Immunol. 2010. PMID: 20463104 Free PMC article. Clinical Trial.
Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.
Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G. Nilsson C, et al. Among authors: biberfeld g. AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15. AIDS Res Hum Retroviruses. 2014. PMID: 24090081 Free PMC article. Clinical Trial.
Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity.
Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, Robb M, Cox J, Michael N, Marovich M, Biberfeld G, Sandström E, Wahren B. Gudmundsdotter L, et al. Among authors: biberfeld g. Vaccine. 2009 Jul 16;27(33):4468-74. doi: 10.1016/j.vaccine.2009.05.018. Epub 2009 May 29. Vaccine. 2009. PMID: 19450644 Free PMC article. Clinical Trial.
318 results